Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease NIJMEGEN, the Netherlands – 7 November 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease (PMD), today announced...

Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol NIJMEGEN, the Netherlands – 18 January, 2021: Khondrion, a clinical-stage biopharmaceutical company...